On April 24, 2024, bluebird bio, Inc. received a notice from The Nasdaq Stock Market LLC indicating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to a delay in filing its Annual Report on Form 10-K for the year ended December 31, 2023. The company has until June 24, 2024, to submit a plan to regain compliance and may be granted an extension until October 14, 2024, to file the report. The delay is attributed to the need to restate financial statements for the year ended December 31, 2022, and unaudited financial information for the first three quarters of 2023 and 2022. The restatements are related to the identification of embedded leases and the treatment of non-lease components in lease agreements, which are not expected to impact...Show More

On April 24, 2024, bluebird bio, Inc. received a notice from The Nasdaq Stock Market LLC indicating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to a delay in filing its Annual Report on Form 10-K for the year ended December 31, 2023. The company has until June 24, 2024, to submit a plan to regain compliance and may be granted an extension until October 14, 2024, to file the report. The delay is attributed to the need to restate financial statements for the year ended December 31, 2022, and unaudited financial information for the first three quarters of 2023 and 2022. The restatements are related to the identification of embedded leases and the treatment of non-lease components in lease agreements, which are not expected to impact the company's cash position or revenue. bluebird bio intends to submit a compliance plan before the deadline and file the 2023 Form 10-K as soon as possible. The company issued a press release on April 26, 2024, to announce the receipt of the Nasdaq notice. The notice does not immediately affect the listing of the company's securities on Nasdaq.